Xoft Showcases Interim Clincal Results for Breast Cancer Product and New Indications for Electronic Brachytherapy(eBx) at Ast...(is data is very exciting as it confirms ...),Health

The Symposium program, titled "Electronic Brachytherapy: Innovation and Conversations" will also feature a panel of leading radiation oncologists and breast surgeons discussing new indications for Electronic Brachytherapy, including the treatment of endometrial cancer and intraoperative radiation therapy. Program highlights include:

-- Not Just for APBI Anymore -- the Latest Indications for Electronic Brachytherapy: With the clearance from FDA for the practice of radiation oncology, the Axxent System has now established itself as an oncology platform technology. Adam Dickler, MD, Department of Radiation Oncology, Little Company of Mary Hospital, Evergreen Park, IL, will review early experience with Xoft Axxent Vaginal cylinders in the treatment of endometrial cancer and Little Company's early experience utilizing the Axxent System to deliver Intraoperative Radiation Therapy (IORT) for early-stage breast cancer patients. With IORT, eligible patients can have their tumors removed and potentially receive their entire regimen of radiation therapy in a single day.

-- What's Next? Electronic Brachytherapy and the Future of Radiation Oncology: Without the need for a heavily-shielded vault, the accessibility of the Axxent Electronic Brachytherapy System can significantly expand the reach of radiation oncology. Mark Carol, MD, Xoft Chief Medical Officer and renowned thought leader in advances in oncology, will discuss the potential for current and next generation treatments using the Axxent X-ray Source.

-- Lightning Round: Two luminaries in the area of APBI will challenge each other and the audience with thought provoking ideas and opinions on these latest breakthroughs in breast cancer treatment. Presented by Peter Beitsch, MD, d
'/>"/>